Page 56 - 2021_09-Haematologica-web

F. Barbaglio et al.
2012;24(6):643-649.
14. Thompson PA, Burger JA. Bruton's tyrosine
kinase inhibitors: first and second genera- tion agents for patients with chronic lym- phocytic leukemia (CLL). Expert Opin Investig Drugs. 2018;27(1):31-42.
15. Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2014;111(38):13906-13911.
16. Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with ibrutinib inhibits BTK- and VLA-4-depen- dent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res. 2015;21(20):4642-4651.
17. Chen SS, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, sig- naling and function in chronic lymphocytic
leukemia. Leukemia. 2016;30(4):833-843. 18. Pasikowska M, Walsby E, Apollonio B, et al. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood.
2016;128(4):563-573.
19.Belloni D, Heltai S, Ponzoni M, et al.
Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018;103(4):707-716.
20. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
21. Burger JA, Burger M, Kipps TJ. Chronic lym-
phocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone mar- row stromal cells. Blood. 1999;94(11):3658- 3667.
22. Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946.
23. Schiattone L, Ghia P, Scarfo L. The evolving treatment landscape of chronic lymphocytic leukemia. Curr Opin Oncol. 2019;31(6):568- 573.
24. Burger JA. The CLL cell microenvironment. Adv Exp Med Biol. 2013;792: 25-45.
25. Badar T, Burger JA, Wierda WG, O'Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol. 2014;7(6):705- 717.
2344
haematologica | 2021; 106(9)